Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
When choosing a treatment center for a myeloproliferative neoplasm (MPN), you want a team of experienced and compassionate experts. The team at Dana-Farber Brigham Cancer Center has extensive experience caring for patients with MPNs. Patients with MPNs are cared for by expert oncologists in our Adult Leukemia Program.
Exceptional Care for MPN Patients
A highly specialized program focusing on MPN diagnostics, treatment, and research
Access to clinical trials exploring new treatments, based on promising scientific discoveries
Consultations and second opinions for patients and physicians nationally and internationally
Access to the latest diagnostics, such as molecular and genomic profiling, including the Rapid Heme Panel, available only to patients at our center
Ability to schedule your first appointment the same day or the next day
Collaboration with our internationally recognized bone marrow/stem cell transplantation program, if appropriate
The full expertise of two renowned medical centers: Dana-Farber Cancer Institute and Brigham and Women's Hospital
Care plans tailored to the needs of each patient, from the first meeting through long-term monitoring
Access to support programs such as nutrition services, social work support, integrative therapies, and survivorship programs
Myeloproliferative neoplasms (MPNs) are a group of blood disorders that occur when the bone marrow makes too many red blood cells, white blood cells, or platelets. There are different types of MPNs, depending on what type of cell is produced in a greater amount. The most common forms are:
Myeloproliferative neoplasms are rare blood disorders. Approximately 20,000 new cases are diagnosed in the U.S. each year. MPNs generally develop after age 50. They are chronic conditions that individuals can manage and live with for a long time if treated properly. However, some can be more aggressive and develop into an acute leukemia.
Some patients with MPNs have no known risk factors for developing the disease. Some recognized risk factors are:
Most individuals usually do not experience many symptoms before an MPN diagnosis. Some general symptoms may include:
Symptoms usually develop over time and get worse if the MPN is not treated.
These symptoms can have many causes and may not be due to cancer. However, it is important that you discuss persistent symptoms with your primary care doctor.
MPNs are chronic conditions, which means most individuals live for a long time with these disorders if they are treated properly. Rarely, some patients' diseases may develop to a more aggressive disease. Essential thrombocytosis and polycythemia vera may develop into myelofibrosis, acute leukemia, or MDS. Myelofibrosis may develop into acute myeloid leukemia. It is important to obtain an accurate diagnosis and treatment to manage these disorders.
New Patient Appointments